Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 2Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Disease 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Sulfonylurea Compounds × 1 year × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡